Skip to main content
    N

    Nuwellis Inc (NUWE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.55
    +0.02 (+4.38%)

    Market Cap: $2.27M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    82%(31/38)
    Avg Surprise
    -8.28%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.39
    Range$-0.39 - $-0.39
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.35-11.4%
    60d ago$-0.33-18.2%
    30d ago$-0.33-18.2%
    7d ago$-0.33-18.2%
    Current$-0.39
    Revenue Consensus
    $3M
    Range$3M - $3M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.22
    Range$-0.22 - $-0.22
    1 analysts
    Revenue Consensus
    $13M
    Range$13M - $13M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.22---
    Sep 26EST
    		-$-0.39---
    Jun 26
    Reported Aug 13
    		$-26.64$-23.80-11.93%Miss+98.8%
    Mar 26
    Reported May 12
    		$-73.15$-35.00-109.00%Miss+92.8%
    Dec 25
    Reported Mar 10
    		$-1.50$-1.56+3.85%Beat-240.9%
    Sep 25
    Reported Nov 12
    		$19.60N/A+103.25%Beat-99.2%
    Jun 25
    Reported Aug 14
    		$-2134.65$-661.50-222.70%Miss+92.3%
    Mar 25
    Reported May 13
    		$-1014.30$-661.50-53.33%Miss-168950.0%
    Dec 24
    Reported Mar 11
    		$-0.44$-0.43-2.33%Miss+100.0%
    Sep 24
    Reported Nov 11
    		$2557.81$-1881.60+235.94%Beat+102.7%
    Jun 24
    Reported Aug 13
    		$-27709.56$-12120.18-128.62%Beat+85.2%
    Mar 24
    Reported May 7
    		$-0.60$-1.06+43.40%Beat+100.0%
    Dec 23
    Reported Mar 5
    		$-115248.35$-71515.71-61.15%Beat-2304867.0%
    Sep 23
    Reported Nov 7
    		$-93124.78$-160181.48+41.86%Beat+90.7%
    Jun 23
    Reported Aug 8
    		$-187793.06$-207001.12+9.28%Beat+81.2%
    Mar 23
    Reported May 9
    		$-261820.06$-430123.29+39.13%Beat+73.8%
    Dec 22
    Reported Feb 28
    		$-5.00N/A+70.74%Beat+87.8%
    Sep 22
    Reported Nov 8
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 22
    Reported Aug 9
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 22
    Reported May 10
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 21
    Reported Mar 1
    		$-41.00$-47.67+13.99%Beat+73.9%
    Sep 21
    Reported Nov 9
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 21
    Reported Aug 10
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 21
    Reported May 11
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 20
    Reported Mar 2
    		$-157.00$-191.00+17.80%Beat+95.3%
    Sep 20
    Reported Nov 10
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 20
    Reported Aug 4
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 20
    Reported May 12
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 19
    Reported Mar 3
    		$-3360.00$-2400.00-40.00%Miss+86.6%
    Sep 19
    Reported Nov 5
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 19
    Reported Aug 6
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 19
    Reported May 7
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 18
    Reported Feb 20
    		$-25110.00$-22680.00-10.71%Miss+86.6%
    Sep 18
    Reported Nov 6
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 18
    Reported Aug 7
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 18
    Reported May 8
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 17
    Reported Mar 20
    		$-187320.00$-52920.00-253.97%Beat-380.6%
    Sep 17
    Reported Oct 31
    		$-1000000.00$-1000000.00+0.00%Beat-
    Jun 17
    Reported Aug 8
    		$-1000000.00$-1000000.00+0.00%Beat-
    Mar 17
    Reported May 9
    		$-1000000.00$-1000000.00+0.00%Beat-
    Dec 16
    Reported Mar 2
    		$-38976.00N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.01EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-125.60%Operating Margin-160.90%
    ROE-609.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.97xQuick Ratio1.54x
    Trading Statistics
    Beta0.09Avg Volume2.94M
    52-Week High$172.9052-Week Low$0.44

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.65
    SMA 20$0.73
    SMA 50$0.92
    SMA 200$30.18
    EMA 10$0.64
    EMA 20$0.72
    EMA 50$1.96
    EMA 200$73.22

    MACD

    Line: -0.14Signal: -0.15Hist: 0.02

    ADX

    ADX: 16.0+DI: 14.9-DI: 23.1

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down96.0
    PSAR$0.70

    Bollinger Bands

    Upper Band$0.92
    Lower Band$0.53
    %B Position5328%(Upper)
    Band Width0.05

    RSI (14-Day)

    Neutral
    30.4

    Momentum Oscillators

    Stoch %K17.8
    Stoch %D9.9
    Williams %R-69.9
    ROC (10d)-26.1%
    Momentum-0.20
    CCI (20d)-167.3
    MFI (14d)25.8

    Volatility Measures

    ATR (14d)$0.14(25.0%)
    StdDev (20d)0.10
    Hist Vol88.7%(High)

    Volume Flow

    VWAP$0.55
    OBV688.4M
    AD Line5641.7B
    CMF (20d)-0.456

    Volume Metrics

    Avg Vol (20d)265.7K
    Vol Ratio0.4x(Low)
    VWMA (20d)$0.78

    Pivot Points

    R3$0.79
    R2$0.71
    R1$0.62
    Pivot Point$0.53
    S1$0.44
    S2$0.36
    S3$0.27

    Advanced Oscillators

    TSI-32.26
    Ultimate Osc29.4
    KST-256.75

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.97M$2.40M$2.42M$2.22M$1.73M$1.90M$2.32M$2.37M$2.19M$1.86M$2.55M$2.41M
    Cost of Revenue$471,000$719,000$770,000$772,000$767,000$837,000$967,000$711,000$720,000$666,000$1.16M$1.03M
    Gross Profit$1.50M$1.68M$1.65M$1.45M$958,000$1.07M$1.35M$1.66M$1.47M$1.19M$1.39M$1.38M
    Operating Expenses$4.67M$6.25M$4.10M$4.14M$3.86M$4.13M$3.74M$3.19M$3.79M$5.94M$4.98M$4.54M
    R&D$942,000$1.73M$884,000$603,000$675,000$550,000$831,000$486,000$558,000$1.33M$1.37M$1.12M
    SG&A$3.73M$4.52M$3.21M$3.54M$3.19M$3.58M$2.91M$2.70M$3.24M$4.61M$3.61M$3.43M
    Operating Income$-3,169,000$-4,568,000$-2,443,000$-2,697,000$-2,906,000$-3,060,000$-2,387,000$-1,532,000$-2,320,000$-4,749,000$-3,593,000$-3,164,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$1.66M$0$0$0$9.64M$0$0$0$5.40M$0$1.91M$204,000
    Income Before Tax$-4,828,000$-4,541,000$-2,422,000$468,000$-12,549,000$-3,013,000$-1,467,000$2.36M$-7,723,000$-4,328,000$-5,507,000$-3,368,000
    Income Tax Expense$0$0$-1,000$0$4,000$1,000$1,000$0$2,000$2,000$2,000$2,000
    Net Income$-4,828,000$-4,541,000$-2,422,000$468,000$-12,553,000$-3,014,000$-1,468,000$2.36M$-7,725,000$-4,330,000$-5,509,000$-3,370,000
    EBITDA$-4,791,000$-4,503,000$-2,061,000$511,000$-12,499,000$-2,940,000$-1,378,000$2.43M$-7,648,000$-4,252,000$-1,915,000$-3,284,000
    EBIT$-4,828,000$-4,541,000$-2,422,000$468,000$-12,549,000$-3,013,000$-1,461,000$2.36M$-7,723,000$-4,328,000$-5,507,000$-3,368,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NUWE

    Government Contracts

    Gov Obligations (TTM)
    $20000
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24225P1357Department of Veterans AffairsDepartment of Veterans Affairs$20000Aug 21, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Nuwellis forms Pediatric Advisory Board to adva...

    Nuwellis has announced the formation of a Pediatric Medical & Nursing Advisory Board, set to convene in November 2026. This board will guide the development of Vivian™...

    Pluang•10/9/26•Bullish

    Nuwellis to convene advisory board for pediatric therapy platform By Investing.com

    Nuwellis, Inc. (NASDAQ:NUWE) announced it will host a Medical & Nursing Advisory Board meeting on November 18-19, 2026...

    Investing.com Nigeria•10/8/26•Bullish

    Nuwellis to hold advisory board meeting for pediatric CRRT system

    Nuwellis, Inc. announced an upcoming Medical & Nursing Advisory Board meeting on November 18-19, 2026, to advance the development of its Vivian pediatric continuous renal replacement therapy (CRRT) system. The meeting...

    StreetInsider•10/8/26•Somewhat-Bullish

    About a dozen pediatric clinicians will assess a kidney-treatment system for children as small as 2.5 kilograms.

    Nuwellis (Nasdaq: NUWE) is convening a pediatric Medical & Nursing Advisory Board on November 18–19, 2026, to advance the development of its Vivian™ pediatric continuous renal replacement therapy (CRRT) system. This...

    Stock Titan•10/8/26•Somewhat-Bullish

    Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

    Nuwellis, Inc. (Nasdaq: NUWE) announced its participation in four major medical conferences in October, focusing on pediatrics, critical care...

    The Manila Times•10/1/26•Bullish

    NUWE Valuation and Fair Value

    P/E
    -0.0x
    P/B
    -0.0x
    See GNG's fair value

    NUWE Profitability: Margins, ROIC and FCF

    Operating margin
    -160.9%
    Net margin
    -125.6%
    ROE
    -609.0%

    NUWE Competitors

    CompanyTicker
    Scisparc LtdSPRC
    Im Cannabis CorpIMCC
    Virax Biolabs Group Limited Ordinary SharesVRAX
    Qualigen Therapeutics IncQLGN
    Flora Growth CorpFLGC
    Clearside Biomedical IncCLSD
    Elevai Labs, Inc. Common StockELAB
    BioRestorative Therapies IncBRTX

    Sector: Healthcare

    NUWE Bull Case vs Bear Case

    Bull case

    • NUWE grew quarterly revenue 14.1% year over year.

    Bear case

    • NUWE has a -125.6% net profit margin.
    • NUWE beat EPS estimates in 37.5% of its last 8 reported quarters.

    NUWE Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -7.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.39
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About NUWE

    Does NUWE pay dividends?

    Nuwellis Inc (NUWE) does not currently pay a regular dividend.

    What is NUWE's market cap?

    Nuwellis Inc (NUWE) has a market capitalization of $2.27M with a current stock price of $0.55.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In